A Phase 3 interventional study of UT-15C (treprostinil diolamine) in Pulmonary Arterial Hypertension, sponsored by United Therapeutics. Completed at 153 sites in 23 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-06-02.
Sponsored by United Therapeutics · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 44 studies testing treprostinil in Pulmonary Arterial Hypertension — 3 open to participants now, 5 under way, 2 of them phase 3. treprostinil · Pulmonary Arterial Hypertension.
Among the 44 studies testing treprostinil in Pulmonary Arterial Hypertension, this one is the 3rd largest by enrollment, is one of 2 that started in 2013, is one of 14 in phase 3, and was the 21st registered.
700 studies on the registry are indexed under Pulmonary Arterial Hypertension; 141 are open to participants now.
Browse Pulmonary Arterial Hypertension studies →3 of the 44 studies testing treprostinil in Pulmonary Arterial Hypertension are open now, in 1 country. Recruiting first, the newest first:
Liquidia Technologies, Inc. · Sites in United States
Ages 18–80
University of Arizona · Sites in United States
Ages 18+
Shanghai Zhongshan Hospital
Ages 18–75
By country, each count listing its studies:
treprostinil: first FDA approval 2002 (REMODULIN), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →
Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
44 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 2 started in 2013.
This study's enrollment of 471 is above the median of 40 across 478 interventional studies indexed under Pulmonary Arterial Hypertension.
Median enrollment 32 across the 44 interventional studies. Of the 32 that completed or were terminated, 20 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
38 of 44 have an industry lead sponsor. The 10 most frequent:
United Therapeutics is the lead sponsor of 85 studies on the registry; 8 are open to participants now.
Of its 17 completed or terminated interventional studies of FDA-regulated products, 15 (88%) have results posted.
51 studies in Pulmonary Arterial Hypertension by United Therapeutics: 1 open now, 3 under way, 1 of them phase 3. Of 40 finished, 28 (70%) have results posted.
Among the 51 studies in Pulmonary Arterial Hypertension by United Therapeutics, this one is the 5th largest by enrollment of the 45 interventional ones that give a count, is one of 5 that started in 2013, is one of 17 in phase 3, and was the 26th registered.
United Therapeutics’s Pulmonary Arterial Hypertension studies by the year they started, since 2002.
1 of the studies testing treprostinil in Pulmonary Arterial Hypertension that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07759804Liquidia Technologies, Inc.A Study of Inhaled Treprostinil (LIQ861) in Adults With Pulmonary Arterial Hypertension Transitioning From Oral Selexipag | 2027-05 |
Add it to your calendar (.ics) → With an account.
Among the 44 studies testing treprostinil in Pulmonary Arterial Hypertension, from their registry updates:
Among United Therapeutics’s 51 in Pulmonary Arterial Hypertension:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study is an international, multi-center, open-label study designed to provide oral treprostinil (UT-15C) to eligible subjects with pulmonary arterial hypertension who have completed the TDE-PH-310 study. The purpose of this study is to assess the long-term safety of UT-15C and to assess the effects of long-term treatment with UT-15C on exercise capacity.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Open label access
Drug: UT-15C (treprostinil diolamine)
UT-15C extended release oral tablet three times daily
Number of Adverse Events
All subjects who received oral treprostinil in TDE-PH-311 were included in the Safety population. All AEs were captured from the time the ICF was signed. All AEs were followed until resolution (or return to normal or baseline values), until they were judged by the Investigator to no longer be clinically significant, or for up to 30 days if the AE extended beyond the final visit. All SAEs were followed until resolution, death, or the subject was lost to follow-up, even if they were ongoing more than 30 days after completion of the final visit. The overall summary of AEs includes the number of subjects with any AE, the number of subjects with any study drug-related AEs, the number of subjects with AEs leading to study drug withdrawal, the number of subjects with any serious AEs, the number of subjects with any severe AEs, and the number of subjects with any study drug-related severe/serious AEs. AEs were coded using the Medical Dictionary for Regulatory Activities.
Time frame: Participants will be followed every 12 weeks, at minimum, until they discontinue the study or the study is discontinued by the sponsor or for a period up to 2.5 years
Change in 6-Minute Walk Distance From Baseline
A summary of change from Baseline in 6MWD at Week 48 for the Safety Population is provided. The Safety Population is all subjects who received oral treprostinil in TDE-PH-311.
Time frame: Baseline to Week 48
Change in Borg Dyspnea Score From Baseline to Week 48
Change in Borg Dyspnea Score from at Week 48 is provided for the Safety Population (all subjects who received oral treprostinil in TDE-PH-311). The Borg Dyspnea Scale is a 0 to 10 rated numerical score used to measure dyspnea as reported by the patient during submaximal exercise and was administered during six-minute walk testing (6MWT), one of the most common and frequently used measures to assess disease severity in PAH. The numbers on the scale are as follows: 0 (no shortness of breath \[SOB\]), 0.5 (very very slight SOB), 1 (very slight SOB), 3 (moderate SOB), 4 (somewhat severe SOB), 5 (severe SOB), 7 (very severe SOB), 9 (very very severe SOB), 10 (maximal SOB).
Time frame: Baseline to Week 48
Change From Baseline to Week 48 in WHO Functional Class
Change from Baseline at Week 48 in WHO FC in the Safety Population (all subjects who received oral treprostinil in TDE-PH-311). The World Health Organization functional classification (WHO-FC) is a clinician-rated assessment used widely to assess PAH severity and functioning. Class I (least severe): Patients are without limitation of physical activity. Class II: Patients are comfortable at rest. Ordinary physical activity causes undue dyspnea or fatigue, chest pain or near syncope. Class III: Marked limitation of physical activity. They are comfortable at rest. Class IV (most severe): Inability to carry out any physical activity without symptoms. These patients manifest signs of right heart failure.
Time frame: Baseline to Week 48
Change in N-terminal Pro-brain Natriuretic Peptide (NT-proBNP) From Baseline to Week 48
Change in N-terminal pro-brain natriuretic peptide from Baseline at Week 48 for the Safety Population (any subject who received oral treprostinil in TDE-PH-311)
Time frame: Baseline to Week 48
| Milestone | UT-15C |
|---|---|
| Started | 470 |
| Completed | 272 |
| Not completed | 198 |
| Withdrew: Adverse event | 63 |
| Withdrew: Death | 69 |
| Withdrew: Lost to follow-up | 8 |
| Withdrew: Protocol violation | 8 |
| Withdrew: Withdrawal by subject | 24 |
| Withdrew: Progressive disease | 20 |
| Withdrew: Other reason not specified | 6 |
All subjects who received oral treprostinil in TDE-PH-311 were included in the Safety population. All AEs were captured from the time the ICF was signed. All AEs were followed until resolution (or return to normal or baseline values), until they were judged by the Investigator to no longer be clinically significant, or for up to 30 days if the AE extended beyond the final visit. All SAEs were followed until resolution, death, or the subject was lost to follow-up, even if they were ongoing more than 30 days after completion of the final visit. The overall summary of AEs includes the number of subjects with any AE, the number of subjects with any study drug-related AEs, the number of subjects with AEs leading to study drug withdrawal, the number of subjects with any serious AEs, the number of subjects with any severe AEs, and the number of subjects with any study drug-related severe/serious AEs. AEs were coded using the Medical Dictionary for Regulatory Activities.
| events | UT-15C |
|---|---|
| Adverse Event | 450 |
| Study Drug Related AE | 362 |
| AE Leading to Study Drug Withdrawal | 126 |
| Serious AE | 206 |
| Severe AE | 182 |
| Study Drug Related Severe AE | 67 |
| Study Drug Related Serious AE | 37 |
A summary of change from Baseline in 6MWD at Week 48 for the Safety Population is provided. The Safety Population is all subjects who received oral treprostinil in TDE-PH-311.
| meters | UT-15C |
|---|---|
| Change in 6-Minute Walk Distance From Baseline | 20.1 ± 79.6 |
Change in Borg Dyspnea Score from at Week 48 is provided for the Safety Population (all subjects who received oral treprostinil in TDE-PH-311). The Borg Dyspnea Scale is a 0 to 10 rated numerical score used to measure dyspnea as reported by the patient during submaximal exercise and was administered during six-minute walk testing (6MWT), one of the most common and frequently used measures to assess disease severity in PAH. The numbers on the scale are as follows: 0 (no shortness of breath \[SOB\]), 0.5 (very very slight SOB), 1 (very slight SOB), 3 (moderate SOB), 4 (somewhat severe SOB), 5 (severe SOB), 7 (very severe SOB), 9 (very very severe SOB), 10 (maximal SOB).
| score on a scale | UT-15C |
|---|---|
| Change in Borg Dyspnea Score From Baseline to Week 48 | -0.49 ± 1.92 |
Change from Baseline at Week 48 in WHO FC in the Safety Population (all subjects who received oral treprostinil in TDE-PH-311). The World Health Organization functional classification (WHO-FC) is a clinician-rated assessment used widely to assess PAH severity and functioning. Class I (least severe): Patients are without limitation of physical activity. Class II: Patients are comfortable at rest. Ordinary physical activity causes undue dyspnea or fatigue, chest pain or near syncope. Class III: Marked limitation of physical activity. They are comfortable at rest. Class IV (most severe): Inability to carry out any physical activity without symptoms. These patients manifest signs of right heart failure.
| score on a scale | UT-15C |
|---|---|
| Change From Baseline to Week 48 in WHO Functional Class | -0.2 ± 0.6 |
Change in N-terminal pro-brain natriuretic peptide from Baseline at Week 48 for the Safety Population (any subject who received oral treprostinil in TDE-PH-311)
| pg/mL | UT-15C |
|---|---|
| Change in N-terminal Pro-brain Natriuretic Peptide (NT-proBNP) From Baseline to Week 48 | -179.23 ± 1968.99 |
Collected over AEs were recorded for each subject throughout the course of the study from Baseline to 30 days following the final study visit (up to 356 weeks).. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| UT-15C | 74/470 (15.7%) | 206/470 (43.8%) | 467/470 (99.4%) |
| Event | UT-15C |
|---|---|
| Pulmonary hypertensionRespiratory, thoracic and mediastinal disorders | 57/470 |
| PneumoniaInfections and infestations | 32/470 |
| Right ventricular failureCardiac disorders | 22/470 |
| Cardiac failureCardiac disorders | 19/470 |
| Septic shockInfections and infestations | 9/470 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 8/470 |
| Acute kidney injuryRenal and urinary disorders | 7/470 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 7/470 |
| DiarrhoeaGastrointestinal disorders | 6/470 |
| GastroenteritisInfections and infestations | 6/470 |
| Event | UT-15C |
|---|---|
| HeadacheNervous system disorders | 328/470 |
| DiarrhoeaGastrointestinal disorders | 311/470 |
| FlushingVascular disorders | 201/470 |
| NauseaGastrointestinal disorders | 188/470 |
| VomitingGastrointestinal disorders | 147/470 |
| DizzinessNervous system disorders | 120/470 |
| Upper respiratory tract infectionInfections and infestations | 116/470 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 113/470 |
| Pain in jawMusculoskeletal and connective tissue disorders | 103/470 |
| Pulmonary hypertensionRespiratory, thoracic and mediastinal disorders | 103/470 |
All 470 subjects who received oral treprostinil during this study are included in the Baseline Analysis Population.
| Age, Categorical(Participants) | UT-15C |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 398 |
| >=65 years | 72 |
| Age, Continuous(years) | UT-15C |
|---|---|
| Mean | 47.2 ± 15.1 |
| Sex: Female, Male(Participants) | UT-15C |
|---|---|
| Female | 374 |
| Male | 96 |
| Ethnicity (NIH/OMB)(Participants) | UT-15C |
|---|---|
| Hispanic or Latino | 135 |
| Not Hispanic or Latino | 334 |
| Unknown or Not Reported | 1 |
| Race (NIH/OMB)(Participants) | UT-15C |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 213 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 10 |
| White | 245 |
| More than one race | 0 |
| Unknown or Not Reported | 2 |
| Etiology of Pulmonary Arterial Hypertension (PAH)(Participants) | UT-15C |
|---|---|
| Idiopathic of Heritable PAH | 299 |
| Collagen Vascular Disease | 114 |
| HIV Infection | 8 |
| Congenital Heart Defect | 38 |
| Other | 11 |
| Background PAH Therapy at Randomization in Parent Study(Participants) | UT-15C |
|---|---|
| Phosphodiesterase Type 5 Inhibitor (PDE5-I) Alone/Soluble Guanylate Cyclase (sGC) Stimulator Alone | 348 |
| Endothelin Receptor Antagonist (ERA) alone | 122 |
| Time since Diagnosis(years) | UT-15C |
|---|---|
| Mean | 3.16 ± 2.69 |
2 further baseline measures are reported on the registry.
Showing the first 100 of 153 sites across 23 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Sep 2013 to primary completion in Aug 2021, 95 months.
Results were first posted in Jun 2022, 9 months after primary completion.
Of 43 industry-sponsored phase 3 interventional studies under Pulmonary Arterial Hypertension, half reached primary completion within 50 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 83. This study's 95 months is above that.
Counting every sponsor, half of 49 studies reached it within 50 months; a quarter within 31 and three quarters within 83.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Treprostinil
Pulmonary Arterial Hypertension →